SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of June, 2015
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address
of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits
the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82 -
EXHIBIT
NUMBER |
|
DESCRIPTION |
| |
|
|
| 99.1 |
|
News
Release Dated June 15, 2015 - Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 9th International
Conference on Oncolytic Virus Therapeutics |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Oncolytics Biotech Inc.
(Registrant) |
| |
|
|
| |
|
|
| Date:
June 15, 2015 |
By: |
/s/ Kirk Look |
| |
|
Kirk Look |
| |
|
Chief Financial Officer |
Exhibit 99.1
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN®
Preclinical Data at the 9th International Conference on Oncolytic Virus Therapeutics
CALGARY, June 15, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics")
(TSX:ONC) (NASDAQ:ONCY) today announced that a series of oral and poster presentations are being made by the Company's research
collaborators at the 9th International Conference on Oncolytic Virus Therapeutics being held from June 13th
to 16th, 2015 in Boston MA.
"Our preclinical program continues to identify new potential
therapeutic combinations as well as advance our understanding of how REOLYSIN® works," said Dr. Brad Thompson,
President and CEO of Oncolytics. "This work is an important part of the ongoing development of our proprietary formulation
of the human reovirus."
Dr. Richard Vile is making an oral presentation regarding
previously disclosed findings around augmenting tumor-specific natural killer (NK) responses and specifically attenuating tumor-specific
immunosuppression. These data also suggest that the combination of PD-1 inhibition therapy with reovirus oncolytic/immunotherapy
represents a readily translatable method to enhance the therapeutic efficacy.
The first abstract/poster titled "Targeting peripheral
and lymph node resistant CLL with combination reovirus therapy," was authored by Melcher, et al. The authors studied chronic
lymphocytic leukemia ("CLL") and the problems associated with eradicating minimal residual disease and drug resistance.
They concluded that the combination of reovirus and ABT-263 could increase direct and immune-mediated killing of peripheral disease
and that reovirus in combination with Fludarabine may be useful in targeting drug-resistant lymph node disease.
The second abstract/poster titled "Oncolysis by reovirus
as an immune priming mechanism with VSV-cDNA immunological boosting treats large established tumors," was authored by Melcher,
et al. The authors looked at the treatment of established B16 melanoma tumors in a mouse model. They concluded that the local killing
of cancer cells by one virus primed the immune system and, by using tumor antigens expressed from a second virus, it was possible
to generate potent immunological responses that led to the rejection of well established tumors.
The third abstract/poster titled "Monocyte carriage and
delivery of reovirus-antibody complexes for melanoma oncolysis," was authored by Melcher, et al. The authors studied preexisting
antiviral immunity and found evidence that there is an alternative mechanism by which systemically administered reovirus may gain
access to tumors, even in the presence of neutralizing antibodies.
Copies of the abstracts and posters, when available, will
be found on the Oncolytics website at: http://www.oncolyticsbiotech.com/for-investors/presentations.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including the Company's expectations related to preclinical work and the Company's
belief as to the potential of REOLYSIN® as a cancer therapeutic, involve known and unknown risks and uncertainties,
which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy
of REOLYSIN® as a cancer treatment, the tolerability of REOLYSIN® outside a controlled test,
the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN®,
uncertainties related to the research, development and manufacturing of pharmaceuticals, changes in technology, general changes
to the economic environment and uncertainties related to the regulatory process. Investors should consult the Company's quarterly
and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating
to the forward-looking statements. Investors should consider statements that include the words "believes", "expects",
"anticipates", "intends", "estimates", "plans", "projects", "should",
or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. Investors
are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking
statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
%CIK: 0001129928
For further information: please contact: TMX Equicom, Nick
Hurst, 300 5th Ave. SW, 10th Floor, Calgary, Alberta T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@tmxequicom.com; TMX
Equicom, Michael Moore, San Diego, CA, Tel: 858.886.7813, mmoore@tmxequicom.com; Dian Griesel, Inc., Susan Forman, 335 West 38th
Street, 3rd Floor, New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 15-JUN-15